Developing Oncolytic Virus to Treat Glioblastoma-Michelle Chen, Ph.D.-04/29/2014 - 8:30am

Event Information
Event Topic: 
Developing Oncolytic Virus to Treat Glioblastoma
Event Date: 
04/29/2014 - 8:30am
Event Location: 
Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA
Speaker Information
Event Speaker: 
Michelle Chen, Ph.D.
Event Speaker Title: 
Chief Business Officer
Event Speaker Company: 
Event Speaker Bio: 

Michelle Chen, PhD, Chief Business Officer, joined DNAtrix in 2013 with a track record of successful leadership roles in business development, marketing and R&D. Most recently she was a business development executive at Hoffmann-La Roche responsible for global oncology licensing, collaborations and M&A. She also chaired the oncology opportunity review committee and served as the external partnership representative in the Avastin Franchise Team. Prior to this role, she led the personalized medicine effort and developed Rx/Dx pharma partnerships in Asia and US on behalf of Ventana (a member of Roche group). Dr. Chen started her biotech career in early drug discovery & development at Scios and later Abgenix as a group leader working on the assay development of antibody drugs, one of which was approved by FDA (aka “Vectibix”) for colorectal cancer. She then went on to gain commercial experience at Agilent Technologies and Applied Biosystems respectively, where she led a dozen new product launches with P&L responsibility, delivered double-digit revenue growth for the business units of more than $200 million, and helped build a new molecular diagnostics incubator at Agilent. Dr. Chen received a PhD in Biochemistry from the University of Washington, followed by the post-doctoral work at UCSF and bioinformatics training at Stanford University.

Event Details
Event Details: 

Bio2Device Group, Tuesday Morning, April 29, 2014

Topic: “Developing Oncolytic Virus to Treat Glioblastoma”
Speaker: Michelle Chen, PhD, Chief Business Officer, DNAtrix
Date and Time: Tuesday, April 29, 2014, 8:30 am
Location: Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA
Cost: No fee and no need to register for morning meetings

Topic Description
DNAtrix’s DNX-2401 is an oncolytic virus designed specifically for treating Glioblastoma (the most aggressive brain tumor), for which there is no cure. DNX-2401 has been evaluated in a Phase I dose-escalation study at the MD Anderson Cancer Center and easily met its key safety endpoint with no product-related toxicities. Remarkably, direct injection of DNX-2401 into human brain tumors also led to extensive tumor killing with no harm to normal brain cells. Patient survival was prolonged potentially with several complete responders, and one patient in remission 25 months post-treatment. Once approved by regulatory authorities, DNX-2401 could be used to treat virtually all cases of high-grade glioma.